Alex Zhavoronkov

Country: Russia
Company: Insilico Medicine
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (, a leading clinical-stage biotechnology company developing next-generation artificial intelligence and robotics platforms for drug discovery. Under his leadership Insilico raised over $400 million in multiple rounds from expert investors, opened R&D centers in six countries or regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions, nominated 8 preclinical candidates, and entered human clinical trials with AI-discovered novel target and AI-designed novel molecule. He is also the founder and of Deep Longevity, Inc, a spin-off of Insilico Medicine developing a broad range of artificial intelligence-based biomarkers of aging and longevity servicing healthcare providers and life insurance industry. In 2020 Deep Longevity was acquired by Endurance Longevity (HK: 0575).
Visit Website